Skip to main content

Peer Review reports

From: SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer

Original Submission
25 Feb 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
17 Mar 2022 Reviewed Reviewer Report
19 Mar 2022 Reviewed Reviewer Report
4 Apr 2022 Author responded Author comments - Hong-Yu Wei
Resubmission - Version 4
4 Apr 2022 Submitted Manuscript version 4
8 Apr 2022 Author responded Author comments - Hong-Yu Wei
Resubmission - Version 5
8 Apr 2022 Submitted Manuscript version 5
14 Apr 2022 Reviewed Reviewer Report
18 Apr 2022 Reviewed Reviewer Report
20 Apr 2022 Author responded Author comments - Hong-Yu Wei
Resubmission - Version 6
20 Apr 2022 Submitted Manuscript version 6
28 Apr 2022 Author responded Author comments - Hong-Yu Wei
Resubmission - Version 7
28 Apr 2022 Submitted Manuscript version 7
1 May 2022 Author responded Author comments - Hong-Yu Wei
Resubmission - Version 8
1 May 2022 Submitted Manuscript version 8
Publishing
9 May 2022 Editorially accepted
17 May 2022 Article published 10.1186/s12920-022-01266-0

You can find further information about peer review here.

Back to article page